Drug Trial Radar · NCT07760818
A Study to Assess Efficacy and Safety of Efgartigimod in Adults With Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory Polyneuropathy (SERENITY)
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
75
Planned (sponsor's estimate)
Start
Oct 9, 2026
Primary completion
Jul 28, 2028
Study completion Jul 28, 2029
Sponsor
- Lead sponsor
- argenxargenx (ARGX)
- Sponsor type
- Industry
- First posted
- Aug 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to assess the efficacy and safety of efgartigimod PH20 in adults with Sjogren's Disease (SjD) associated with nerve damage. The study will assess how efgartigimod PH20 affects symptoms of SjD specifically linked to the peripheral nervous system; the safety and tolerability of efgartigimod PH20; and whether receiving efgartigimod PH20 affects the participant's quality of life.
Conditions
- Sjogrens Disease
- Primary Sjögren's Syndrome Painful Sensory Neuropathies
Interventions
efgartigimod PH20 SCBiological
subcutaneous efgartigimod PH20 SC given by prefilled syringe
Placebo PH20 SCOther
subcutaneous placebo PH20 SC given by prefilled syringe
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in modified Toronto Clinical Neuropathy Score (mTCNS) total score at the end of Part ATime frame: Up to 48 weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Sarasota Arthritis Research Center
Sarasota, Florida · Recruiting
Vantage Clinical Trials Tampa
Tampa, Florida · Recruiting
Revive Research Institute Inc
Sterling Heights, Michigan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.